Years advancing rare-disease diagnostics.Âą
Exomes and genomes sequenced.²
Higher diagnostic yield than chromosomal microarray.Âł
Your most trusted partner for clinical genomics
Fueled by one of the largest rare-disease data sets,2,4 GeneDx’s offers comprehensive genetic testing from industry-leading, whole exome and genome testing to targeted panels that convert complex genomic information into clear clinical answers that can:
- Unlock personalized health plans for patients
- Accelerate drug discovery
- Improve health-system efficiencies
With nearly one million sequenced exomes and genomes,2 advanced interpretation tools, and a team of expert scientists and clinicians, GeneDx gives providers actionable insights faster—helping reduce the diagnostic odyssey and improve outcomes.5
Dedicated to advancing the field of genomics, so more patients get answers
GeneDx has identified more than 500 new disease-gene relationships7 and developed novel tools for genomic data analysis8—meaning more answers for more patients.
Real families, real answers
Families across the country have found clarity with GeneDx, ending years of uncertainty and opening doors to better care.
Meet Carlotta & Andrea
"Carlotta was undiagnosed for 18 months until we were finally able to access whole exome sequencing to identify the underlying cause of her issues: PIGN-CDG. While it doesn’t necessarily change her immediate prognosis, it does change what the long-term prognosis could be. We wouldn’t have options if we didn’t understand what exactly it was that we were dealing with.”—Andrea
Meet William
William missed some early motor milestones, experienced speech delays and stiff muscles, and exhibited behaviors consistent with autism. Ordering exome sequencing as a first-line genetic test could have uncovered answers within weeks. But because William’s doctors waited for signs and symptoms, it took over 7 years—and the onset of seizures—to receive a definitive diagnosis.â€
